April 11 is the World Parkinson’s Disease Day and marks the birthday of Dr. J Parkinson who first described the disease in “An Essay on the Shaking Palsy” 201 years ago. The month of April is dedicated to raise awareness of the Parkinson’s disease.
Parkinson’s disease is the second most common neurological disease, affecting more than 6 million people worldwide. The disease is expected to lead to an increasing social and economic burden on societies as the population ages.
Parkinson’s disease is a progressive disease of the nervous system that affects the ability to move due to reduced levels of dopamine in the brain. Tremor is the best know sign of the disease. Compared to Alzheimer’s disease – the most common neurodegenerative disease – Parkinson’s disease affects a younger patient group, which means that many affected still are at working age, with considerable financial consequences for the individual and society.
The unmet medical need of Parkinson’s disease is high due to the lack of pharmaceutical agents affecting the underlying pathology in this disorder. Current treatments are symptomatic and do not halt or modify the disease progression. This means that the condition of the patients with Parkinson’s disease will gradually deteriorate and that the disease will eventually limit the patients’ possibilities to work and live a normal and independent life.
Gunilla Osswald, CEO of BioArctic: “BioArctic’s most important task is to improve the quality of life for patients with diseases in the central nervous system. We strive to transform the treatment regimen of neurodegenerative diseases like Parkinson’s disease. Together with our partner AbbVie we are truly committed to do our outmost to bring an innovative disease modifying treatment to the large number of patients suffering from Parkinson’s disease.”